SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Andrew H who wrote (13276)1/13/1998 6:24:00 PM
From: Henry Niman  Respond to of 32384
 
Andy, The LLY programs I mentioned all involve Rexinoids (Targretin, LGD1268, LGD1324?) and of course all involve LGND. LLY's Prozac is going off patent in 2002 and they need blockbusters on the market by then (which is why they are aslo seeking to boost Evista's effectiveness with rexinoids such as Targretin).



To: Andrew H who wrote (13276)1/13/1998 6:27:00 PM
From: Henry Niman  Respond to of 32384
 
Andy, GLYC compunds in theory are great, Problem is getting effective dose in patients. They include MMPIs (matrix metalloproteinase inhibitors) which block metastasis and other proteins that interfer with cell surface communication. BBIOY is worth Billions on the promise of MMPIs and AGPH and others have programs.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News